Rational use of diuretics in acute decompensated heart failure

Current Heart Failure Reports

Volumn 5, Issue 3, 2008, Pages 153-162

  Goebel, Jason A ^a   Van Bakel, Adrian B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALDOSTERONE ANTAGONIST; BUMETANIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CONIVAPTAN; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOLAZONE; MORPHINE; NAXIFYLLINE; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO; ROLOFYLLINE; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; VASOPRESSIN RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NITRATE; VASOPRESSIN RECEPTOR;

ACUTE HEART FAILURE; ADD ON THERAPY; BLOOD DYSCRASIA; CELL HYPERPLASIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIURESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTROPHY; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOURICEMIA; INDIVIDUALIZATION; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; LONG TERM CARE; MALAISE; METABOLIC ACIDOSIS; MONOTHERAPY; NEUROLOGIC DISEASE; OTOTOXICITY; PANCREATITIS; PARESTHESIA; PHOTOSENSITIVITY; PROBLEM PATIENT; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SODIUM BLOOD LEVEL; ULTRAFILTRATION; ACUTE DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; HEART FAILURE; NATRIURESIS; SYNDROME; VASOCONSTRICTION;

ACUTE DISEASE; ALDOSTERONE ANTAGONISTS; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FUROSEMIDE; HEART FAILURE; HUMANS; NATRIURESIS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NITRATES; RECEPTORS, PURINERGIC P1; RECEPTORS, VASOPRESSIN; SODIUM CHLORIDE SYMPORTER INHIBITORS; SYNDROME; ULTRAFILTRATION; VASOCONSTRICTION;

EID: 55249084409     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-008-0024-y     Document Type: Review

References (61)

1. American Heart Association, American Stroke Association: Heart Disease and Stroke Statistics - 2008 Update. Available at http://www.americanheart.org/downloadable/heart/ 1200078608862HS_Stats%202008.final.pdf. Accessed July 21, 2008.
2. Fonarow GC, Acute Decompensated Heart Failure National Registry (ADHERE) Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): Opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003, 4(Suppl 7):S21-S30.
3. Brater DC: Diuretic therapy. N Engl J Med 1998, 339:387-395.
4. Brater DC: Diuretic pharmacokinetics and pharmacodynamics. In The In Vivo Study of Drug Action: Principles and Applications of Kinetic-Dynamic Modeling. Edited by van Boxtel CJ, Holford NHG, Danhof M. Amsterdam: Elsevier Science; 1992:253-275.
5. Cleland JGF, Coletta A, Witte K: Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 2006, 119(12 Suppl 1):S26-S36.
6. Voelker JR, Cartwright-Brown D, Anderson S, et al.: Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987, 32:572-578.
7. Knauf H, Mutschler E: Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995, 26:394-400.
8. Ellison DH: Diuretic therapy and resistance in congestive heart failure. Cardiology 2001, 96:132-143.
9. Kaissling B, Stanton BA: Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1988, 255:F1256-F1268.
10. Shankar SSF Brater DC: Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003, 284:F11-F21.
11. Dormans TP, Gerlag PG: Combination of high dose furosemide and hydrochlorothiazide in the treatment of refractory heart failure. Eur Heart J 1996, 17:1867-1874.
12. Dormans TP, van Meyel JJ, Gerlag PG, et al.: Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J Am Coll Cardiol 1996, 28:376-382.
13. Aaser E, Gullestad L, Tollofsrud S, et al.: Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997, 57:361-367.
14. Mojtahedzadeh M, Salehifar E, Vazin A, et al.: Comparison of hemodynamic and biochemical effects of furosemide by continuous infusion and intermittent bolus in critically ill patients. J Infus Nurs 2004, 27:255-261.
15. Salvador DR, Rey NR, Ramos GC, et al.: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, 3:CD003178.
16. Stanton BA, Kaissling B: Adaptation of distal collecting duct to increased sodium delivery. Am J Physiol 1988, 255:F1269-F1275.
17. Fliser D, Schröter M, Neubeck M, et al.: Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994, 46:482-488.
18. Oster JR, Epstein M, Smoller S: Combined therapy with thiazide type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983, 99:405-406.
19. Epstein M, Lepp BA, Hoffman DS, et al.: Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977, 21:656-667.
20. Neuberg GW, Miller AB, O'Connor CM, et al.: Diuretic resistance predicts mortality in patients with advanced heart failure (Prospective Randomized Amlodipine Survival Evaluation). Am Heart J 2002, 144:31-38.
21. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) [no authors listed]. Arch Intern Med 1993, 153:154-183.
22. Cooper HA, Dries DL, Davis CE, et al.: Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
23. Francis GS, Siegel RM, Goldsmith SR, et al.: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohormonal axis. Ann Intern Med 1985, 103:1-6.
24. Packer M: Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Eur Heart J 1990, 11(Suppl D):44-52.
25. Johnston GD, Nicholls DP, Leahey WJ: The dose-response characteristics of the acute non-diuretic peripheral vascular effects of furosemide in normal subjects. Br J Clin Pharmacol 1984, 18:75-81.
26. Bayliss J, Norell M, Canepa-Anson R, et al.: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987, 57:17-22.
27. Benedict CR, Weiner DH, Johnstone DE, et al.: Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the Studies of Left Ventricular Dysfunction (SOLVD) registry. The SOLVD Investigators. J Am Coll Cardiol 1993, 22(Suppl A):146A-153A.
28. Levine TB, Francis GS, Goldsmith SR, et al.: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982, 49:1659-1666.
29. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 10:709-717.
30. Weber KT, Brilla CG: Pathological hypertrophy and the cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
31. Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355-1364.
32. Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
33. Wang W: Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994, 24:571-575.
34. Struthers AD: Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996, 2:47-54.
35. Butler J, Forman DE, Abraham WT, et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
36. Forman DE, Butler J, Wang Y, et al.: Incidence, predicators at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:62-67.
37. Knight EL, Glynn RJ, McIntyre KM, et al.: Predictors of decreased renal function with heart failure during ACE-I therapy: Results from studies of left ventricular function (SOLVD). Am Heart J 1999, 138:849-855.
38. Nohria A, Haselblad V, Stebbins A, et al.: Cardiorenal interactions: insight from the ESCAPE trial. J Am Coll Cardiol 2008, 51:1268-1274.
39. Papavassiliou V, Anderton M, Loftus IM, et al.: The physiological effects of elevated intra-abdominal pressure following aneurysm repair. Eur J Vas Endovasc Surg 2003, 26:293-298
40. Damman K, Navis G, Smilde TDJ, et al.: Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007, 9:872-878
41. Liang KV, Williams AW, Green EL, et al.: Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008, 36(Suppl 1):S75-S88.
42. Cotter G, Metzkor E, Kaluski E, et al.: Randomized trial of high-dose isosorbide dinitrate plus low dose furosemide versus high dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary edema. Lancet 1998, 351:389-393.
43. Johnson W, Omland T, Hall C, et al.: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002, 39:1623-1629.
44. The Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Investigators: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002, 287: 1531-1540.
45. Sackler-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
46. Owan TE, Chen HH, Frantz RP, et al.: The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail 2008, 14:267-275.
47. Walker BR, Childs ME, Adams EM: Direct cardiac effects of vasopressin: the role of V1 and V2 vasopressinergic receptors. Am J Physiol 1988, 255:H261-H265.
48. Gheorghiade M, Konstam MA, Burnett JC Jr, et al.: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
49. Konstam MA, Gheorghiade M, Burnett JC Jr, et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
50. Vallon V, Miracle C, Thompson S: Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 2008, 10:176-187.
51. Gottlieb SS, Skettino SL, Wolff A, et al.: Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000, 35:56-59.
52. Gottlieb SS, Brater DC, Thomas I, et al.: Effects of BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.
53. Givertz MM, Massie BM, Fields TK, et al.: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, 50:1551-1560.
54. Dittrich HC, Gupta DK, Hack TC, et al.: The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007, 13:609-617.
55. van Vliet AA, Donker AJM, Nauta JJ, et al.: Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993, 71:21A-28A.
56. Kreimeir U, Bruckner UB, Schmidt J, et al.: Instantaneous restoration of regional organ blood flow after severe hemorrhage: Effect of small volume resuscitation with hypertonic-hyperoncotic solutions. J Surg Res 1990, 49:493-503.
57. Licata G, Di Pasquale P, Parrinello G, et al.: Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus in refractory congestive heart failure: Long-term effects. Am Heart J 2003, 145:459-466.
58. Hillege HL, Girbes AR, de Kam PJ, et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
59. Guazzi MD, Agostoni P, Perego G, et al.: Apparent paradox of neurohormonal axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 1994, 72:534-539.
60. Costanzo MR, Guglin ME, Saltzberg MT, et al.: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.
61. Klabunde RD: Cardiovascular pharmacology concepts. Available at http://www.cvpharmacology.com/diuretic/diuretics.htm. Accessed July 21, 2008.